Stefania Bellone, PhD
Associate Research Scientist in Obstetrics, Gynecology, and Reproductive SciencesDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Associate Research Scientist in Obstetrics, Gynecology, and Reproductive Sciences
Appointments
Obstetrics, Gynecology & Reproductive Sciences
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of Brescia (2003)
- MS
- University of Genova (1999)
Research
Copy Link
Overview
Dr. Stefania Bellone's research has been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals. Dr. Bellone’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. She is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma. Her research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies. Dr. Bellone has initiated and completed multiple investigator’s initiated FDA approved clinical trials in gynecologic patients using novel immunotherapeutic strategies developed and characterized in Dr. Alessandro Santin's laboratory.
ORCID
0000-0001-5909-5292
Research at a Glance
Yale Co-Authors
Frequent collaborators of Stefania Bellone's published research.
Publications Timeline
A big-picture view of Stefania Bellone's research output by year.
Alessandro Santin, MD
Blair C. McNamara, MD
Natalia Buza, MD
Yang Yang, PhD
Cem Demirkiran, MD
Elena Ratner, MD, MBA
101Publications
1,859Citations
Publications
2025
A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.Peer-Reviewed Original ResearchImmunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis
Ettorre V, Bellone S, Buza N, Hui P, Hartwich T, Demirkiran C, Greenman M, Sethi N, Palmieri L, Santin A. Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis. Gynecologic Oncology 2025, 202: 131-136. PMID: 41092695, DOI: 10.1016/j.ygyno.2025.09.017.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsUterine serous carcinomaWhole-exome sequencingFluorescent-in-situ hybridizationNext generation sequencingHER2-positiveSerous carcinomaImmunohistochemistry stainingCorrelation of HER2HER2-Targeted TherapyHER2-targeted treatmentTissue blocksGeneration sequencingTreatment-eligible patientsComprehensive whole-exome sequencingEvaluation of patientsNext generation sequencing dataNext generation sequencing platformsFluorescence in situ hybridizationUSC patientsHER2 testingERBB2 amplificationHER2 expressionTherapeutic optionsRetrospective analysisHER2Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantEffective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts
Ettorre V, Demirkiran C, Bellone S, Hartwich T, Greenman M, McNamara B, Sethi N, Palmieri L, Santin A. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecologic Oncology 2025, 201: 195-202. PMID: 40907200, DOI: 10.1016/j.ygyno.2025.08.027.Peer-Reviewed Original ResearchAltmetricConceptsTrophoblast cell surface antigen 2Primary cervical cancer cell linesAntibody-directed cellular cytotoxicityCervical cancer cell linesIn vivo anti-tumor activityAntibody-drug conjugatesCancer cell linesTumor cell deathTumor cellsNon-expressing cell linesCell linesTrophoblast cell surface antigen 2 expressionPreclinical pharmacologyClinical evaluationExpression of trophoblast cell surface antigen 2Cervical cancer mouse modelMedian overall survivalNegative tumor cellsCancer mouse modelCervical cancer patientsTumor growth suppressionCervical carcinoma cell linesCell deathCarcinoma cell linesMarkers of apoptosisPreclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Santin N, Sethi N, Bellone S, Demirkiran C, Ettorre V, Greenman M, McNamara B, Buza N, Hartwich T, Palmieri L, Lorusso D, Santin A. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications 2025, 5: 1611-1620. PMID: 40862536, PMCID: PMC12423748, DOI: 10.1158/2767-9764.crc-25-0251.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsEndometrial cancer cell linesTrophoblast antigen 2Antibody-dependent cell cytotoxicityAntibody-drug conjugatesEndometrial cancer xenograftsCancer cell linesEndometrial cancerPreclinical activityBystander killingCancer xenograftsCell linesPreclinical evidenceIn vivo activityCell cytotoxicityTargeted treatmentPrimary tumor cell linesBiomarker-targeted therapiesNovel antibody-drug conjugatesControl ADCRecurrent endometrial cancerChromium release assayFlow cytometry-based assayTumor growth inhibitionIn vivoCytometry-based assayTET3 is a common epigenetic immunomodulator of pathogenic macrophages
Liu B, Dai Y, Wang Z, Song J, Du Y, Lv H, Bellone S, Yang Y, Kennedy A, Zhang S, Venkatachalapathy M, Surovtseva Y, Wang P, Carmichael G, Taylor H, Zhang X, Li D, Huang Y. TET3 is a common epigenetic immunomodulator of pathogenic macrophages. Journal Of Clinical Investigation 2025, 135: e194879. PMID: 40794443, PMCID: PMC12578387, DOI: 10.1172/jci194879.Peer-Reviewed Original ResearchThis study investigates the role of TET3 in promoting pathogenic macrophages across chronic inflammatory diseases, and shows that selectively eliminating TET3-overexpressing macrophages (“Toe-Macs”) can mitigate disease progression in conditions like MASH, NSCLC, and endometriosis.Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsCS cell linesPreclinical activityTROP2 expressionPresence of peripheral blood lymphocytesTopoisomerase I inhibitor payloadCell linesRare gynecologic tumorsChromium release assayResistance to chemotherapyTumor growth suppressionPeripheral blood lymphocytesIn vivoAntibody-drug conjugatesOvarian carcinosarcomaRecurrence rateGynecological tumorsNo significant differencePreclinical resultsHealthy donorsBlood lymphocytesPoor prognosisMouse xenograftsChromium releaseClinical trialsCell cytotoxicityPreclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models
Ettorre V, Demirkiran C, Bellone S, Niu N, Buza N, Sethi N, Hartwich T, Palmieri L, Santin A. Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models. International Journal Of Gynecological Cancer 2025, 35: 101988. PMID: 40680453, DOI: 10.1016/j.ijgc.2025.101988.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsLow-grade serous ovarian cancerTrophoblast cell surface antigen 2Serous ovarian cancerTrophoblast cell surface antigen 2 expressionSacituzumab govitecanOvarian cancerPatient-derived xenograftsPreclinical activityResistance to chemotherapyPDX modelsAromatase inhibitorsDisease resistant to chemotherapySerous ovarian cancer casesEpithelial ovarian cancer subtypesEffective new treatment optionPatient-derived xenograft modelsSevere combined immunodeficient miceModerate to strong expressionOvarian cancer casesIndolent disease courseOvarian cancer subtypesStandard treatment modalityNew treatment optionsCohort of patientsIn vivoA phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significancePreclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTrophoblast cell surface antigen 2Uterine serous carcinomaAntibody-dependent cell-mediated cytotoxicityAntibody-drug conjugatesCell-mediated cytotoxicitySerous carcinomaPreclinical activityCell linesTargets trophoblast cell-surface antigen-2Presence of peripheral blood lymphocytesTreatment of uterine serous carcinomaInduce antibody-dependent cell-mediated cytotoxicityPrimary USC cell linesRecurrent uterine serous carcinomaUSC xenograftsUterine serous carcinoma cell linesAntigen 2In vivoPrimary tumor cell linesTROP2 overexpressionBiomarker-targeted therapiesControl ADCChromium release assayHigher recurrence rateTumor growth suppression
News
Copy Link
News
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 09, 2024
Topical Shows Promise in Treating Precancerous Cervical Condition
- July 07, 2023Source: Medicine
Bibliometric and Visualized Analysis of Highly Cited Articles on Immunotherapy for Endometrial Cancer
- October 27, 2022
New Findings on Endometrial Cancer Treated With Pembrolizumab
Get In Touch
Copy Link